Evidence map›Paper›PMID 39171140›Full record

ArticleMolecular therapy. Nucleic acids2024

Bi-functional CpG-STAT3 decoy oligonucleotide triggers multilineage differentiation of acute myeloid leukemia in mice.

Dongfang Wang, Damian Kaniowski, Karol Jacek, Yu-Lin Su, Chunsong Yu, Jeremy Hall, Haiqing Li, Mingye Feng, Susanta Hui, Bożena Kaminska and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. STAT3 signaling inhibitors for cancer treatment.Trends in pharmacological sciences · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Dongfang WangDepartment of Immuno-Oncology, Beckman Research Institute at City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Damian KaniowskiDepartment of Immuno-Oncology, Beckman Research Institute at City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Karol JacekLaboratory of Molecular Neurobiology, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Warsaw, Poland.
Yu-Lin SuDepartment of Immuno-Oncology, Beckman Research Institute at City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Chunsong YuDepartment of Immuno-Oncology, Beckman Research Institute at City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Jeremy HallDepartment of Immuno-Oncology, Beckman Research Institute at City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Haiqing LiIntegrative Genomics Core, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Mingye FengDepartment of Immuno-Oncology, Beckman Research Institute at City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Susanta HuiDepartment of Radiation Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Bożena KaminskaLaboratory of Molecular Neurobiology, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Warsaw, Poland.
Vittorio DeFranciscisInstitute of Genetic and Biomedical Research (IRGB), CNR, 20090 Milan Italy.
Carla Lucia EspositoInstitute for Experimental Endocrinology and Oncology "Gaetano Salvatore" (IEOS), CNR, 80100 Naples, Italy.
Annalisa DiRuscioHarvard Medical School Initiative for RNA Medicine, Harvard Medical School, Boston, MA 02115, USA.
Bin ZhangDepartment of Hematologic Malignancies Translational Science, Beckman Research Institute at City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Guido MarcucciDepartment of Hematologic Malignancies Translational Science, Beckman Research Institute at City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Ya-Huei KuoDepartment of Hematologic Malignancies Translational Science, Beckman Research Institute at City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Marcin KortylewskiDepartment of Immuno-Oncology, Beckman Research Institute at City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3M
Myeloid cell-selective, oligonucleotide-based STAT3 inhibition combined with total marrow and lymphoid irradiation for immunotherapy of acute myeloid leukemiaR01CA284593 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Susanta K Hui, Marcin Kortylewski · 2023 to 2026
$2.8M
Targeting Transcriptional Regulators for Immunotherapy of Acute Myeloid LeukemiaR01CA213131 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI KORTYLEWSKI, MARCIN · 2017 to 2021
$2.1M
NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA213131NCI NIH HHS R01 CA284593
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) cells resist differentiation stimuli despite high expression of innate immune receptors, such as Toll-like receptor 9 (TLR9). We previously demonstrated that targeting Signal Transducer and Activator of Transcription 3 (STAT3) using TLR9-targeted decoy oligodeoxynucleotide (CpG-STAT3d) increases immunogenicity of human and mouse AML cells. Here, we elucidated molecular mechanisms of inv(16) AML reprogramming driven by STAT3-inhibition/TLR9-activation

Indexed as

acute myeloid leukemiacancer immunotherapyCpG deoxynucleotidesdecoy DNAMT: Oligonucleotides: Therapies and ApplicationsOligonucleotide therapeuticsSTAT3TLR9

Identifiers

PMID39171140
PMCPMC11338104

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.